These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23299776)

  • 1. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
    Teitelbaum A; Ba-Mancini A; Huang H; Henk HJ
    Oncologist; 2013; 18(1):37-45. PubMed ID: 23299776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total cost comparison in relapsed/refractory multiple myeloma.
    Durie B; Binder G; Pashos C; Khan Z; Hussein M; Borrello I
    J Med Econ; 2013; 16(5):614-22. PubMed ID: 23281721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
    Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
    Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
    Gaultney JG; Franken MG; Tan SS; Redekop WK; Huijgens PC; Sonneveld P; Uyl-de Groot CA
    J Clin Pharm Ther; 2013 Feb; 38(1):41-7. PubMed ID: 23126374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma.
    Hollmann S; Moldaver D; Goyert N; Grima D; Maiese EM
    J Manag Care Spec Pharm; 2019 Apr; 25(4):449-459. PubMed ID: 30917078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
    Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
    J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
    Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
    J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
    Gay F; Hayman SR; Lacy MQ; Buadi F; Gertz MA; Kumar S; Dispenzieri A; Mikhael JR; Bergsagel PL; Dingli D; Reeder CB; Lust JA; Russell SJ; Roy V; Zeldenrust SR; Witzig TE; Fonseca R; Kyle RA; Greipp PR; Stewart AK; Rajkumar SV
    Blood; 2010 Feb; 115(7):1343-50. PubMed ID: 20008302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Fayter D; Wolff R; Armstrong N; Stirk L; Worthy G; Albuquerque de Almeida F; Kleijnen J; Al MJ
    Pharmacoeconomics; 2018 Feb; 36(2):145-159. PubMed ID: 29086363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with thalidomide and lenalidomide in multiple myeloma.
    Moehler T
    Curr Cancer Drug Targets; 2012 May; 12(4):372-90. PubMed ID: 22229246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.
    Garrison LP; Wang ST; Huang H; Ba-Mancini A; Shi H; Chen K; Korves C; Dhawan R; Cakana A; van de Velde H; Corzo D; Duh MS
    Oncologist; 2013; 18(1):27-36. PubMed ID: 23299777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tale of lenalidomide clinical superiority over thalidomide and regulatory and cost-effectiveness issues.
    Paumgartten FJR
    Cien Saude Colet; 2019; 24(10):3783-3792. PubMed ID: 31577009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.
    Gooding S; Lau IJ; Sheikh M; Roberts P; Wong J; Dickens E; Bullement A; Elvidge J; Lee D; Ramasamy K
    PLoS One; 2015; 10(9):e0136207. PubMed ID: 26367874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Dashputre AA; Gatwood KS; Gatwood J
    J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
    Hornberger J; Rickert J; Dhawan R; Liwing J; Aschan J; Löthgren M
    Eur J Haematol; 2010 Dec; 85(6):484-91. PubMed ID: 20846301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
    Bhutani D; Zonder J; Valent J; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Lum L; Ratanatharathorn V; Uberti J; Abidi MH
    Support Care Cancer; 2013 Sep; 21(9):2437-42. PubMed ID: 23591714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
    Hjorth M; Hjertner Ø; Knudsen LM; Gulbrandsen N; Holmberg E; Pedersen PT; Andersen NF; Andréasson B; Billström R; Carlson K; Carlsson MS; Flogegård M; Forsberg K; Gimsing P; Karlsson T; Linder O; Nahi H; Othzén A; Swedin A;
    Eur J Haematol; 2012 Jun; 88(6):485-96. PubMed ID: 22404182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.